"Two phase 3 trials currently underway are expected to help answer the provocative question of whether ipilimumab will replace interferon as the standard of care for adjuvant therapy in melanoma, according to a presenter at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
“ 'We really have a new path forward and a new beginning,' Lynn M. Schuchter, MD, chief of the division of hematology/oncology and C. Willard professor of medicine at Abramson Cancer Center at the University of Pennsylvania, said during a presentation. 'I’m hopeful we will advance this therapy further by refining proper patient selection, matching the right biomarkers and modifying toxicities.' "
Editor's note: Clinical trials are research studies done with volunteer patients. Learn more about the risks and advantages of trials for patients here. The clinical trials described in this story are testing the ability of the drug ipilimumab to prevent recurrence in patients who have already been treated for stage III and stage IV melanoma. Interferon is currently the standard of care for so-called 'adjuvant therapy' to prevent recurrence, but ipilimumab may soon replace it.